| Exclusion Criteria: | 1) Less than 21 years of age
2) Any type of active invasive cancer
3) Bilateral mastectomy
4) Known allergy to celebrex, aspirin, other NSAIDs or other COX-2 inhibitors, sulfa containing drugs
5) Past or current history of gastrointestinal bleeding, ulcer disease or perforation
6) Past or current history of liver or renal disease
7) Performance status that restricts normal activity for a significant portion of each day
8) Use of oral contraceptives; androgens; luteinizing-hormone-releasing-hormone (LHRH) analogs, prolactin inhibitors, antiandrogens, or steroids. Women who discontinue these drugs at least 3 months prior to study enrollment will be eligible.
9) Psychiatric condition, including history of clinical depression, or addictive disorder that would preclude obtaining informed consent or would interfere with compliance.
10) Use of Celecoxib, tamoxifen, raloxifene, or other SERM therapy (women who discontinue the drugs at least 3 months prior to study enrollment are eligible).
11) Pregnant women or lactating women
12) Presence of saline or silicone breast implants
13) Active bleeding disorder such as qualitative or quantitative platelet abnormalities, hemophilia or von Willebrand syndrome.
14) Presence of ischemic heart disease or abnormal EKG
15) Concomitant Warfarin use
16) Concomitant administration of flucanazole and/or lithium
17) Known genetic predisposition (presence of BRCA1 or BRCA2 mutation)
18) History of cardiovascular diseases that might include one of the following: myocardial infraction, angina, coronary angioplasty, congestive heart failure, stroke, or coronary bypass surgery
19) Uncontrolled hypertension (i.e. - > 135/>85 mm Hg on three repeated measurements during the 6 weeks prior to enrollment on the study
20) Family history of premature coronary disease (i.e. - onset < 55 years of age)
21) Diagnosis of Diabetes
22) Uncontrolled hypercholesteremia [low-density lipoprotein cholesterol (LDL-C) > 130]. Hypercholesteremia needs to be controlled following the updated National Cholesterol Education Program Adult Treatment Panel III Guidelines for at least 3 months prior to enrollment on the study. Hypercholesteremia treatment should continue during the entire period of Celecoxib treatment on the protocol.
23) Smoking history during the 3-years prior to enrollment on the study
24) Metabolic syndrome diagnosis: The diagnosis of metabolic syndrome is made when three or more of these risk factors are present: a. Waist circumference: Men > 102 cm (>40 in.); Women > 88 cm (> 35 in.); b. Triglycerides = 150 mg/dl (=1.69 mmol/L); c. High-density lipoprotein cholesterol (HDL-C): [Men < 40 mg/dl (< 1.03 mmol/L), Women < 50 mg/dl (< 1.29 mmol/L)]; d. Blood pressure = 130/85 mm Hg; e. Fasting glucose = 110 mg/dl (= 6.1 mmol/L)
25) History of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous, family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels
26) Any indications for ASA Deficiency |